FI3930686T3 - Uusia rautakoostumuksia ja menetelmiä niiden valmistamiseksi ja käyttämiseksi - Google Patents
Uusia rautakoostumuksia ja menetelmiä niiden valmistamiseksi ja käyttämiseksi Download PDFInfo
- Publication number
- FI3930686T3 FI3930686T3 FIEP20717359.2T FI20717359T FI3930686T3 FI 3930686 T3 FI3930686 T3 FI 3930686T3 FI 20717359 T FI20717359 T FI 20717359T FI 3930686 T3 FI3930686 T3 FI 3930686T3
- Authority
- FI
- Finland
- Prior art keywords
- composition
- iron
- aqueous
- aqueous iron
- used according
- Prior art date
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims 37
- 239000000203 mixture Substances 0.000 title claims 28
- 229910052742 iron Inorganic materials 0.000 title claims 19
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 claims 3
- 229940032961 iron sucrose Drugs 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 2
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229950003776 protoporphyrin Drugs 0.000 claims 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962812028P | 2019-02-28 | 2019-02-28 | |
| PCT/US2020/020517 WO2020176894A1 (en) | 2019-02-28 | 2020-02-28 | Novel iron compositions and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3930686T3 true FI3930686T3 (fi) | 2023-09-01 |
Family
ID=70190086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20717359.2T FI3930686T3 (fi) | 2019-02-28 | 2020-02-28 | Uusia rautakoostumuksia ja menetelmiä niiden valmistamiseksi ja käyttämiseksi |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11292813B2 (enExample) |
| EP (2) | EP4234020A3 (enExample) |
| JP (3) | JP7320611B2 (enExample) |
| KR (1) | KR20210133243A (enExample) |
| CN (2) | CN119488480A (enExample) |
| AU (2) | AU2020229381A1 (enExample) |
| CA (1) | CA3131596A1 (enExample) |
| DK (1) | DK3930686T3 (enExample) |
| ES (1) | ES2955019T3 (enExample) |
| FI (1) | FI3930686T3 (enExample) |
| HR (1) | HRP20230989T1 (enExample) |
| HU (1) | HUE063182T2 (enExample) |
| LT (1) | LT3930686T (enExample) |
| PL (1) | PL3930686T3 (enExample) |
| PT (1) | PT3930686T (enExample) |
| RS (1) | RS64652B1 (enExample) |
| SG (1) | SG11202109323UA (enExample) |
| SI (1) | SI3930686T1 (enExample) |
| SM (1) | SMT202300276T1 (enExample) |
| WO (1) | WO2020176894A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023541606A (ja) * | 2020-09-11 | 2023-10-03 | レニバス・セラピューティクス・インコーポレイテッド | 腎臓を保護しながらがんを治療するための方法 |
| WO2024069644A1 (en) * | 2022-09-30 | 2024-04-04 | West Bengal Chemical Industries Limited | A pharmaceutically acceptable ferric carboxymaltose and preparation thereof |
| CN115969714B (zh) * | 2022-11-03 | 2025-03-11 | 华熙生物科技股份有限公司 | 具有光谱选择性的防晒组合物及其应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE862482C (de) * | 1950-05-14 | 1953-01-12 | Merck Chem Fab E | Verfahren zur Darstellung haltbarer, injizierbarer Loesungen von Salzen des dreiwertigen Eisens |
| US5624668A (en) | 1995-09-29 | 1997-04-29 | Luitpold Pharmaceuticals, Inc. | Iron dextran formulations |
| DE19547356A1 (de) | 1995-12-19 | 1997-06-26 | Vifor Int Ag | Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung |
| US7300674B2 (en) * | 2000-12-20 | 2007-11-27 | Sheldon Tobe | Sterile low bicarbonate dialysis concentrate solutions |
| ES2315401T3 (es) * | 2002-08-26 | 2009-04-01 | Vifor (International) Ag | Prueba de bioequivalencia para formulaciones que contienen hierro. |
| US7674780B2 (en) * | 2004-03-16 | 2010-03-09 | Navinta Llc | Iron sucrose complexes and method of manufacture thereof |
| ES2424943T3 (es) | 2004-12-06 | 2013-10-10 | Emcure Pharmaceuticals Limited | Un proceso rentable para la preparación de hierro sacarosa |
| ITMO20050056A1 (it) | 2005-03-15 | 2006-09-16 | Biofer Spa | Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi. |
| CN100528237C (zh) | 2005-04-26 | 2009-08-19 | 重庆医药工业研究院有限责任公司 | 多核的氢氧化铁-糖复合物的制备方法 |
| EP1757299A1 (de) * | 2005-08-25 | 2007-02-28 | Vifor (International) Ag | Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung |
| RS52185B (sr) | 2006-10-04 | 2012-10-31 | Infacare Pharmaceutical Corporation | Preparat stansoporfina sa visokim stepenom čistoće |
| EP1947120A1 (de) | 2007-01-19 | 2008-07-23 | Vifor (International) Ag | Eisen-Kohlenhydrat-Komplex-Verbindungen |
| IN269965B (enExample) | 2007-06-25 | 2015-11-27 | Claris Lifescienses Ltd | |
| TWI592159B (zh) | 2007-11-16 | 2017-07-21 | 威佛（國際）股份有限公司 | 藥學組成物 |
| AU2010220396B2 (en) | 2009-03-02 | 2013-10-17 | Vifor (International) Ag | Phosphate adsorbent |
| CN102451185A (zh) * | 2010-10-19 | 2012-05-16 | 长春纳米生技公司 | 金属离子纳米簇组合物 |
| EP2548562A1 (de) | 2011-07-18 | 2013-01-23 | SeBo GmbH | Kombinationstherapie mit Eisen-basierenden Phosphatadsorbern |
| EP2647389A1 (en) * | 2012-04-04 | 2013-10-09 | Charité - Universitätsmedizin Berlin | Magnetic nanoparticle dispersion, its preparation and diagnostic and therapeutic use |
| CN103340827B (zh) * | 2013-07-16 | 2014-12-10 | 成都天台山制药有限公司 | 蔗糖铁注射液及其制法 |
| CN104558064A (zh) * | 2013-10-29 | 2015-04-29 | 北京京卫信康医药科技发展有限公司 | 蔗糖铁的制备方法 |
| IN2013CH05383A (enExample) | 2013-11-21 | 2015-08-28 | Reddy’S Lab Ltd Dr | |
| CN104098616B (zh) | 2014-05-27 | 2016-04-20 | 广西壮族自治区化工研究院 | 一种蔗糖铁的制备方法 |
| AU2015324103C1 (en) * | 2014-09-29 | 2020-08-20 | Fred Hutchinson Cancer Center | Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers |
| US20190106454A1 (en) * | 2016-03-23 | 2019-04-11 | Fred Hutchinson Cancer Research Center | Compounds linked with a saccharide metal complex and uses thereof |
| US20190358242A1 (en) * | 2017-02-08 | 2019-11-28 | Fred Hutchinson Cancer Research Center | Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers |
| EP4559468A3 (en) | 2017-09-11 | 2025-06-25 | Pharmacosmos Holding A/s | Iron complex compounds for therapeutic use |
| CN109912675B (zh) | 2017-12-13 | 2020-09-15 | 北京市林业果树科学研究院 | 一种蔗糖亚铁及其制备方法 |
| CN110063965A (zh) | 2019-06-04 | 2019-07-30 | 吉林省富生医疗器械有限公司 | 一种血液透析浓缩物 |
| CN112315902B (zh) | 2019-08-05 | 2022-05-13 | 南京恒生制药有限公司 | 一种低易变铁含量蔗糖铁注射液制备方法 |
| CN112156109A (zh) | 2020-09-29 | 2021-01-01 | 神奈纳米医药技术(珠海)有限公司 | 氢氧化铁-糖络合物的制备方法及其应用 |
| CA3191492A1 (en) | 2020-09-29 | 2022-04-07 | LG Bionano, LLC | Methods of preparing iron complexes |
| CN112168844A (zh) | 2020-09-29 | 2021-01-05 | 神奈纳米医药技术(珠海)有限公司 | 一种氢氧化铁碳水化合物复合物的制备方法 |
| CN115531414A (zh) | 2021-06-30 | 2022-12-30 | 南京恒生制药有限公司 | 一种新型蔗糖铁复合物及其制备方法 |
| JP2024534172A (ja) | 2021-08-27 | 2024-09-18 | ヴァイフォー（インターナショナル）アーゲー | 鉄組成物並びにそれらを作製及び使用する方法 |
-
2020
- 2020-02-28 DK DK20717359.2T patent/DK3930686T3/da active
- 2020-02-28 KR KR1020217030370A patent/KR20210133243A/ko active Pending
- 2020-02-28 PL PL20717359.2T patent/PL3930686T3/pl unknown
- 2020-02-28 AU AU2020229381A patent/AU2020229381A1/en not_active Abandoned
- 2020-02-28 US US16/805,223 patent/US11292813B2/en active Active
- 2020-02-28 CN CN202411305791.9A patent/CN119488480A/zh active Pending
- 2020-02-28 RS RS20230725A patent/RS64652B1/sr unknown
- 2020-02-28 HR HRP20230989TT patent/HRP20230989T1/hr unknown
- 2020-02-28 JP JP2021550178A patent/JP7320611B2/ja active Active
- 2020-02-28 SI SI202030257T patent/SI3930686T1/sl unknown
- 2020-02-28 LT LTEPPCT/US2020/020517T patent/LT3930686T/lt unknown
- 2020-02-28 EP EP23176202.2A patent/EP4234020A3/en active Pending
- 2020-02-28 CN CN202080031484.XA patent/CN113825496B/zh active Active
- 2020-02-28 WO PCT/US2020/020517 patent/WO2020176894A1/en not_active Ceased
- 2020-02-28 PT PT207173592T patent/PT3930686T/pt unknown
- 2020-02-28 CA CA3131596A patent/CA3131596A1/en active Pending
- 2020-02-28 SM SM20230276T patent/SMT202300276T1/it unknown
- 2020-02-28 HU HUE20717359A patent/HUE063182T2/hu unknown
- 2020-02-28 ES ES20717359T patent/ES2955019T3/es active Active
- 2020-02-28 FI FIEP20717359.2T patent/FI3930686T3/fi active
- 2020-02-28 EP EP20717359.2A patent/EP3930686B1/en active Active
- 2020-02-28 SG SG11202109323UA patent/SG11202109323UA/en unknown
-
2022
- 2022-02-15 US US17/672,072 patent/US11840552B2/en active Active
- 2022-11-02 US US17/979,490 patent/US11834471B2/en active Active
-
2023
- 2023-07-21 JP JP2023118851A patent/JP7646750B2/ja active Active
- 2023-09-07 US US18/243,584 patent/US20240002427A1/en active Pending
-
2025
- 2025-03-04 JP JP2025033475A patent/JP2025084949A/ja active Pending
- 2025-09-10 AU AU2025230678A patent/AU2025230678A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3930686T3 (fi) | Uusia rautakoostumuksia ja menetelmiä niiden valmistamiseksi ja käyttämiseksi | |
| JP2023002544A5 (enExample) | ||
| WO2009033756A3 (en) | Use of oxyntomodulin alone or in combination with melanotropin potentiating factor as a therapeutic agent | |
| MY208749A (en) | Biligand drug conjugates and uses thereof | |
| DK1933833T3 (da) | Terapi til behandling af overaktiv blære | |
| WO2009033755A3 (en) | Use of l-carnosine as a therapeutic agent | |
| WO2009033803A3 (en) | Use of the pentapeptide drlds and gamma-endorphin as therapeutic agents | |
| WO2009033771A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2008024843A3 (en) | Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein | |
| JP2020526553A5 (enExample) | ||
| MA56827A1 (fr) | Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine | |
| KR100515196B1 (ko) | 사이클로스포린 또는 타크롤리무스를 투여함으로써 유발되는 신장 간질의 섬유성 병변이나 손상과 관련된 신독성 또는 신부전 예방용 제약학적 조성물 | |
| WO2009043480A3 (en) | Use of leptin (22-56 ) as a therapeutic agent | |
| RU2014124171A (ru) | Лекарственное средство для терапевтического лечения и/или улучшения состояния при сепсисе | |
| WO2009033748A3 (en) | Use of osteostatin, alone or in combination with thymopentin, as a therapeutic agent | |
| WO2007064448A3 (en) | Cancer treatment using fts and 2-deoxyglucose | |
| JP2019123731A5 (enExample) | ||
| JP2021506907A5 (enExample) | ||
| RU2010146309A (ru) | Фармацевтическая композиция для лечения фибромиалгии | |
| JP2011500650A5 (enExample) | ||
| CN108815171A (zh) | 25-羟基胆固醇在制备治疗或预防心肌梗死的药物中的应用 | |
| CN115590974A (zh) | 功能化靶向制剂及其制备方法、应用 | |
| RU2010114037A (ru) | Применение белка полосы 3 и расар-27 в качестве терапевтического средства | |
| Kononenko et al. | Studying the analgetic activity of plant extracts based on the Chinese poplar (Populu simonii) | |
| WO2024044398A1 (en) | Systems and methods using sulfated glycosaminoglycans (gags) and gag analogs to treat or prevent monkeypox (mpox) |